Please assess the completion status of the following clinical trial:

Trial Title: Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male age 25-65 with documented growth hormone deficiency on stable doses x 3 months (at least) of any hormone replacement therapies and with stable MRIs x 2 years in the setting of a known pituitary mass.~Exclusion Criteria:~* Female gender~* current GH use or GH use within three months of the study~* diabetes~* hypoglycemia~* liver or kidney disease~* use of drugs that could increase GH secretion (i.e. L-dopa)~* alcohol or substance abuse~* use of investigational drugs within four weeks of our study and use of supraphysiologic doses of steroids within the previous six months.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant Human Growth Hormone first (Type: ACTIVE_COMPARATOR): Subjects will take rhGH for eight weeks followed by a two month wash out period and then will cross over to rhIGF1 for eight weeks.
- Recombinant Human IGF-1 (Type: ACTIVE_COMPARATOR): Subjects will take rhIGF1 for eight weeks followed by a two month wash out period and then will cross over to rhGH for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).